ArticleAmerican journal of translational research2021
Clinical characteristics and risk factors of patients with flupirtine-induced liver cirrhosis complicated with upper gastrointestinal bleeding.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Prognostic Analysis of Liver Cirrhosis Patients with Cerebral Infarction and/or Gastrointestinal Hemorrhage: A Retrospective Cohort Study.Computational and mathematical methods in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate clinical characteristics and risk factors of patients with Flupirtine-induced liver cirrhosis complicated with upper gastrointestinal bleeding.
methodsA total of 116 patients with liver cirrhosis admitted to our hospital from July 2018 to July 2019 were selected and divided into bleeding group (liver cirrhosis complicated with upper gastrointestinal bleeding, n = 71) and non-bleeding group (liver cirrhosis, n = 45). The clinical data of patients in the two groups were collected, including general data, liver function, urinalysis, coagulation function and imaging data. Univariate analysis and multivariate logistic regression analysis were utilized to find the influencing factors of liver cirrhosis complicated with upper gastrointestinal bleeding.
resultsOf the 116 patients, 45 patients had upper gastrointestinal bleeding, with an incidence rate of 38.79%, including 18 patients (40.00%) with rupture of esophageal varices, 9 (20.00%) with rupture of gastric varices, 9 (20.00%) of portal hypertensive gastropathy, 8 (17.78%) with peptic ulcer, 1 (2.22%) with acute erosive hemorrhagic gastritis; 14 (31.11%) experienced recurrent hemorrhage within 72 hours after treatment, but no death occurred. There were 45 cases (38.79%) in the bleeding group, and 71 (61.21%) in the non-bleeding group, and the differences in the course of liver cirrhosis, the degree of esophageal varices, peptic ulcer, portal hypertension, non-steroidal drug medication and TP between the bleeding group and non-bleeding group were significant (P < 0.05). Severe esophageal varices, liver cirrhosis, peptic ulcer, portal hypertension, non-steroidal drug medication, and TP ≥ 16 s were found to be risk factors of liver cirrhosis complicated with upper gastrointestinal bleeding by logistic regression analysis.
conclusionClinically, it is necessary to take corresponding intervention measures to reduce the incidence of upper gastrointestinal bleeding in patients with liver cirrhosis and improve the prognosis of patients with liver cirrhosis.
Indexed as
Identifiers
34150161PMC8205751W3176018642What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.